Hims & Hers Health Inc.（纽交所代码：HIMS）在周一收盘后公布了其第四季度业绩。以下是该季度的关键数据。 Hims & Hers Health报告季度GAAP每股收益为0.11美元，符合分析师预期。季度收入为4.8114亿美元，超过了分析师预期的4.7031亿美元，并高于去年同期的2.4662亿美元。 Hims & Hers的订阅用户数量增长至220万，较2023年同比增长45%。第四季度毛利率为77%，较2023年第四季度的83%有所下降。 Hims & Hers Health首席执行官Andrew Dudum表示：“2024年是Hims & Hers非常出色的一年，我们继续构建一个利用个性化和技术的平台，与传统医疗系统截然不同。现在超过200万用户信任Hims & Hers，帮助他们在健康之旅中取得进展，每天都有数以千计的新用户加入。” 展望未来：Hims & Hers预计2025年第一季度收入为5.2亿至5.4亿美元，调整后的息税折旧摊销前利润（EBITDA）为5500万至6500万美元，反映了11%至12%的调整后EBITDA利润率。 公司预计2025年全年收入为23亿至24亿美元，调整后的EBITDA为2.7亿至3.2亿美元，反映了12%至13%的调整后EBITDA利润率。 根据Benzinga Pro的数据，Hims & Hers Health的股价在周一盘后下跌17.66%，至42.25美元。

以上内容来自Benzinga Earnings专栏，原文如下：

Hims & Hers Health Inc. (NYSE:HIMS) reported its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter. 

The Details: Hims & Hers Health reported quarterly GAAP earnings of 11 cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $481.14 million, which beat the analyst consensus estimate of $470.31 million and is an increase over revenue of $246.62 million from the same period last year.

Hims & Hers subscribers grew to 2.2 million, up 45% year-over-year in 2024. Gross margin was 77% for the fourth quarter of 2024 compared to 83% for the fourth quarter of 2023.

Read Next: Palantir Extends Losses, Microsoft Slides: What’s Driving Markets Monday? 

“2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, Hims & Hers Health CEO.

“Over 2 million subscribers now entrust Hims & Hers to aid them in their journey to better health — with thousands more joining daily,” Dudum added.

Outlook: For the first quarter of 2025, Hims and Hers expects revenue of $520 million to $540 million and adjusted EBITDA of $55 million to $65 million, reflecting an adjusted EBITDA margin of 11% to 12%.

For the full year 2025, the company expects revenue of $2.3 billion to $2.4 billion and adjusted EBITDA of $270 million to $320 million, reflecting an adjusted EBITDA margin of 12% to 13%.

HIMS Price Action: According to data from Benzinga Pro, Hims & Hers Health shares are down 17.66% after hours at $42.25 Monday.  

Read Next: 

• Financial Crime Weekly: $1.4 Billion Ethereum Stolen In Largest Crypto Hack Ever, SEC Creates Cyber And Emerging Technologies Unit

Image: Shutterstock